NCT03849105 - 131I-IPA and Concurrent XRT in Recurrent GBM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

July 31, 2022

Study Completion Date

October 31, 2022

Conditions

Glioblastoma Multiforme

Interventions

RADIATION

4-L-[131I]iodo-phenylalanine (131I-IPA)

"Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy"

Trial Locations (5)

1066

The Netherlands Cancer Institute, Amsterdam

1090

Medical University of Vienna, Vienna

2290

Lake Macquarie Private Hospital, Gateshead

3508

UMC Utrecht Cancer Center, Utrecht

4020

Kepler University Clinic, Linz

All Listed Sponsors

lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY